知镜 Cognispect · 医学文献与研究工作台

Hydroxyurea promotes brain development in children with sickle cell anemia.

Cam Y, Zhang J, Dedkov I, Ouyang A, Lewis JB, Binkley MM, Mirro AE, Fellah S, Roberts H, Shimony JS, An H, Lee JM, Ford AL, Fields ME, Guilliams KP.
Brain research bulletin · 2026-07-07 · PMID 42413789

文献摘要

Sickle cell anemia (SCA) is associated with chronic anemia and cerebrovascular dysfunction, leading to progressive brain atrophy. Hydroxyurea (HU), a disease-modifying therapy, improves hematologic parameters and reduces stroke risk, but its long-term effects on brain development remain unclear. Even though clinician guidelines recommend initiation of HU in infancy, there is a persistent underuse of HU. We examined whether HU use initiated during childhood and long-term HU use can mitigate the changes in gray matter volume (GMV), white matter volume (WMV), total brain volume, and cortical thickness in children with SCA. We used FreeSurfer derived volumetrics to conduct historical longitudinal analyses on 330 MRI scans (2004-2024) from participants with SCA and healthy controls to understand the effects of HU on brain development. Linear mixed-effects models showed that SCA participants who started using HU before the age of 9 (+HU 1 yr) had higher total brain volume and GMV compared to those who did not (-HU>1 yr). An interaction between age and long-term HU treatment indicated that long-term HU treatment may be more advantageous at early ages with effects diminishing across development.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。